A pharmaceutical business's regulatory affairs (RA) department is in charge of getting clearance for new pharmaceutical goods and ensuring that approval is maintained for as long as the business wants the product to be on the market. It acts as a liaison between the regulatory authority and the project team, as well as a channel of communication with the regulatory authority as the project progresses, with the goal of ensuring that the project plan accurately anticipates the regulatory authority's requirements before the product is approved. RA is responsible for staying up to date on new legislation, rules, and other regulatory information. In the creation, inspection, quality assurance, and safety assessment of new and current consumable, medicinal, and diagnostic products, regulatory affairs is a mandatory and necessary effort (both ethically and regulatorily).
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Personalized and precision medicine (PPM) can be established as a unique healthcare model through biodesign-driven and inspired biotech, translational applications. This approach aims to ensure human healthcare, wellness, and biosafety.
Sergey Suchkov, Institute for Biotech & Global Health of RosBioTech and A.I. Evdokimov MGMSU, Russian Federation
Title : Monitoring folds localization in ultra-thin transition metal dichalcogenides using optical harmonic generation
Ahmed Raza Khan, Australian National University, Australia
Title : A systematic review of regulatory approaches for Direct- To- Consumers (DTC) genetic testing
Kavitha Palaniappan, Duke-NUS Medical School, Singapore
Title : Regulatory framework of in vitro diagnostic and artificial intelligence for precision medicine
Pei Ting Sarah Chou, Regulatory Affairs Professionals Society, Taiwan
Title : Unraveling cancer stem cell signatures in circulating tumor cells of metastatic colorectal cancer: Investigating ALDH1A1 and the repurposing potential of disulfiram via scRNA-seq
Nurul Syakima Ab Mutalib, Universiti Kebangsaan Malaysia, Malaysia